Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Current Liabilities: 2010-2024

Historic Total Current Liabilities for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $14.0 million.

  • Lineage Cell Therapeutics' Total Current Liabilities fell 32.33% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 32.33%. This contributed to the annual value of $14.0 million for FY2024, which is 22.18% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Total Current Liabilities of $14.0 million as of FY2024, which was down 22.18% from $18.0 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Total Current Liabilities high stood at $47.1 million for FY2021, and its period low was $7.8 million during FY2020.
  • Its 3-year average for Total Current Liabilities is $17.0 million, with a median of $18.0 million in 2023.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 506.46% in 2021, then tumbled by 59.71% in 2022.
  • Lineage Cell Therapeutics' Total Current Liabilities (Yearly) stood at $7.8 million in 2020, then soared by 506.46% to $47.1 million in 2021, then slumped by 59.71% to $19.0 million in 2022, then fell by 5.38% to $18.0 million in 2023, then decreased by 22.18% to $14.0 million in 2024.